BiologicalDrug
Adjuvant clinical trials
- studies test it
- 15
- open now
- 3
- in phase 3
- 1
- first study started
- 2006
Keep track of what changes. Save the Adjuvant studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2020 | 1 |
| 2022 | 3 |
| 2023 | 1 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 7
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 9
Ab&B Bio-tech Co., Ltd.JS (2) · Genocea Biosciences, Inc. (2) · Serum Institute of India Pvt. Ltd. (1) · SOLTI Breast Cancer Research Group (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · MAXVAX Biotechnology Limited Liability Company (1) · PATH (1) · Statens Serum Institut (1)
Often tested with
Tested in the same studies.
GEN-003 (2) · Rabies Vaccines (1) · Neoadjuvant Therapy (1) · CHO Cells (1) · Antigens (1) · CHO cell (1) · Bevacizumab (1) · Toripalimab (1)
Studies
Open first, then newest update. How each study uses Adjuvant is read from its arms, and is right about nine times in ten.
Testing it · 15
- Labyrinthin Vaccination in Veterans With Lung AdenocarcinomaNot yet recruitingPhase 2VA Office of Research and DevelopmentNCT07859592Written as LabVax 3(22)-23 and GM-CSF (adjuvant) in combination with pembrolizumab
- Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine （CHO Cell） in Adults Aged 18 Years and OlderNot yet recruitingPhase 1Yikang Biotech (Suzhou) Co., Ltd.NCT07807449Written as Adjuvant Suspension
- PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal CarcinomaNot yet recruitingPhase 1/2Sun Yat-sen UniversityNCT05341193Written as Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab
- Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and AboveCompletedPhase 1MAXVAX Biotechnology Limited Liability CompanyNCT05636436Written as Low dose adjuvant
- Pfs230D1 + R21 in Matrix-M1 in African School Children and AdultsActive, not recruitingPhase 2Serum Institute of India Pvt. Ltd.NCT07147400Written as MATRIX-M1 (Adjuvant) For Bedside Mixing
- Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast CancerActive, not recruitingPhase 2SOLTI Breast Cancer Research GroupNCT05296746Written as Chemotherapy (adjuvant)
- Clinical Trial of Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and OlderActive, not recruitingPhase 1Ab&B Bio-tech Co., Ltd.JSNCT07421050Written as Subunit Influenza Vaccine (Adjuvant)
- Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and OlderActive, not recruitingPhase 1Ab&B Bio-tech Co., Ltd.JSNCT07421037Written as Quadrivalent Subunit Influenza Vaccine (Adjuvant)
- Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)Active, not recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT05724329Written as Tislelizumab + Dasatinib + Quercetin (adjuvant)
- Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy AdultsCompletedPhase 1PATHNCT04232943Written as E.coli Double Mutant Heat-Labile Toxin (dmLT) (adjuvant)
- Dose Ranging Safety and Efficacy of Therapeutic HSV-2 VaccineCompletedPhase 2Genocea Biosciences, Inc.NCT02114060Written as Matrix-M2 Adjuvant (25μg)
- Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 StudyCompletedPhase 2Genocea Biosciences, Inc.NCT02300142Written as Matrix-M2 Adjuvant (25μg)
- A Safety and Immunogenicity Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31)CompletedPhase 1Statens Serum InstitutNCT01049282Written as Antigen (Ag85B-ESAT-6) with adjuvant (IC31)
- Adjuvant Hepatic Arterial Infusional Chemotherapy After Curative Resection of Hepatocellular CarcinomaCompletedPhase 3Yonsei UniversityNCT01088581Written as Adjuvant group
- Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 AdjuvantCompletedPhase 1Colby Pharmaceutical CompanyNCT00662272Written as Fluzone vaccine with JVRS-100 adjuvant
Given in every arm · 4 — Adjuvant is usual care beside what is tested
- Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant PembrolizumabWithdrawnPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT06116578Written as Pembrolizumab adjuvant
- A Phase ⅠStudy of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-driedCompletedPhase 1Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.NCT03026972Written as Low dose adjuvant
- Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes InfectionTerminatedPhase 2Genocea Biosciences, Inc.NCT03146403Written as Matrix-M2
- Evaluating New Formulation of Therapeutic HSV-2 VaccineCompletedPhase 2Genocea Biosciences, Inc.NCT02515175Written as Matrix-M2
As the comparator · 4 — what is tested is compared with Adjuvant
- Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal CancerTerminatedPhase 3Ralf HofheinzNCT04495088Written as infusional 5-FU/FA "AIO" regimen (adjuvant)
- Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of AgeStatus unknownPhase 1/2Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdNCT02919293Written as Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine(adjuvant)
- Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and OlderCompletedPhase 1SeqirusNCT00848848Written as Trivalent Influenza Vaccine + adjuvant
- Phase 1 Norwalk Vaccine StudyCompletedPhase 1LigoCyte Pharmaceuticals, Inc.NCT00806962Written as Adjuvant/Excipients